Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:50873
Name follicular lymphoma
Definition A B-cell lymphoma that is characterized as an indolent non-Hodgkin's lymphoma and has_material_basis_in follicle center B-cells (centrocytes and centroblasts).
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma follicular lymphoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00577278 Phase II Ibritumomab tiuxetan Methotrexate + Sirolimus + Tacrolimus Rituximab Fludarabine + Melphalan Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed USA 0
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated USA 0
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Terminated USA 0
NCT01193842 Phase Ib/II Vorinostat Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Completed USA 0
NCT01216683 Phase II Bendamustine + Rituximab Bortezomib Lenalidomide Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Active, not recruiting USA 0
NCT01286272 Phase II Bendamustine + Ofatumumab Bendamustine + Bortezomib + Ofatumumab Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT01307267 Phase I Rituximab + Utomilumab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed USA | ITA | FRA 2
NCT01473628 Phase Ib/II Rituximab Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma Active, not recruiting USA 0
NCT01691898 Phase Ib/II Obinutuzumab + Pinatuzumab Vedotin + Rituximab Pinatuzumab Vedotin + Polatuzumab vedotin-piiq + Rituximab Obinutuzumab + Polatuzumab vedotin-piiq A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS) Completed USA | ITA | FRA | DEU | CAN 1
NCT01719250 Phase I Buparlisib Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed USA 0
NCT01732913 Phase III Idelalisib Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated USA | ITA | FRA | ESP | DEU 14
NCT01732926 Phase III Idelalisib Bendamustine + Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated USA | ITA | FRA | ESP | DEU | CAN 9
NCT01796171 Phase Ib/II Lilotomab Betalutin Rituximab A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01) Active, not recruiting USA | ITA | FRA | ESP | CAN | BEL | AUT 17
NCT01804686 Phase III Ibrutinib A Long-term Extension Study of PCI-32765 (Ibrutinib) Enrolling by invitation USA | ITA | FRA | ESP | DEU | CAN | BEL 22
NCT01811368 Phase II anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT01897012 Phase I Romidepsin Alisertib Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Completed USA 0
NCT01953692 Phase I Pembrolizumab A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) Completed 0
NCT01955499 Phase I Ibrutinib + Lenalidomide Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Active, not recruiting USA | CAN 0
NCT01974440 Phase III Ibrutinib Bendamustine + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma Active, not recruiting USA | FRA | ESP | DEU | BEL 14
NCT01976585 Phase Ib/II CDX-301 + Poly ICLC In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy Completed USA 0
NCT01994382 Phase I Cerdulatinib Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma Completed USA 0
NCT02038946 Phase II Nivolumab Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) Completed USA | ITA | FRA | ESP | DEU | CAN | BEL 5
NCT02049541 Phase I Buparlisib + Rituximab Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma Completed USA 0
NCT02082977 Phase I GSK126 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma Terminated USA | FRA 1
NCT02106091 Phase I AFM11 Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL Terminated USA | DEU 2
NCT02187861 Phase II Bendamustine + Rituximab Bendamustine + Rituximab + Venetoclax Rituximab + Venetoclax A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma Completed USA | ITA | FRA | DEU | CAN | BEL 2
NCT02194751 Phase II Oncoquest-L vaccine Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma Not yet recruiting USA 0
NCT02208037 Phase II Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Completed USA 0
NCT02220842 Phase I Atezolizumab + Obinutuzumab A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma Completed USA | ITA | FRA | DEU 1
NCT02254772 Phase Ib/II Ipilimumab + SD-101 TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma Completed USA 0
NCT02257567 Phase Ib/II Bendamustine + Rituximab Polatuzumab vedotin-piiq Obinutuzumab A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma Completed USA | ITA | FRA | ESP | DEU | CAN 7
NCT02266147 Phase Ib/II SD-101 Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma Terminated USA 0
NCT02282358 Phase Ib/II Mocetinostat Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Active, not recruiting USA 0
NCT02320292 Phase III Rituximab Ibritumomab tiuxetan + Rituximab Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma Active, not recruiting USA 0
NCT02339922 Phase II Ixazomib + Rituximab Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT02343536 Phase I Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Azacitidine A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma Completed USA 0
NCT02348216 Phase Ib/II axicabtagene ciloleucel A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) Active, not recruiting USA | FRA | DEU | CAN 2
NCT02367040 Phase III Rituximab Copanlisib Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 30
NCT02369016 Phase III Copanlisib Phase III Copanlisib in Rituximab-refractory iNHL Active, not recruiting ITA 9
NCT02376699 Phase I Pembrolizumab + SEA-CD40 SEA-CD40 Safety Study of SEA-CD40 in Cancer Patients Active, not recruiting USA 0
NCT02381080 Phase I Erythromycin + Ibrutinib + Voriconazole Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy Completed ESP | CAN 1
NCT02384954 Phase Ib/II ALT-803 + Rituximab ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab Terminated USA 0
NCT02393157 Phase II Carboplatin + Etoposide + Ifosfamide + Obinutuzumab Cytarabine Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE) Recruiting USA 0
NCT02401048 Phase Ib/II Durvalumab + Ibrutinib A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas Completed USA 0
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated USA 1
NCT02446457 Phase II Pembrolizumab + Rituximab Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma Recruiting USA 0
NCT02454270 Phase II JNJ-64052781 A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies Terminated USA | FRA | ESP | BEL 1
NCT02457598 Phase I Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies Active, not recruiting USA | FRA 1
NCT02471911 Phase I Dexamethasone Carboplatin + Etoposide + Ifosfamide + Rituximab Selinexor KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma Completed USA 0
NCT02501473 Phase Ib/II GLA-SE + Pembrolizumab Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab With Follicular Non-Hodgkin's Lymphoma Terminated 0
NCT02532192 Phase I Rituximab Cisplatin Dexamethasone Cytarabine Fluconazole Belinostat A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma Withdrawn 0
NCT02532257 Phase II Ibrutinib + Lenalidomide + Rituximab Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma Active, not recruiting USA 0
NCT02536300 Phase III Idelalisib Dose Optimization Study of Idelalisib in Follicular Lymphoma Active, not recruiting ITA | FRA | ESP | CAN 6
NCT02564744 Phase II Naratuximab Emtansine + Rituximab Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL Completed USA | ITA | BEL 6
NCT02576275 Phase III Bendamustine + Rituximab Duvelisib A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) Withdrawn USA 0
NCT02596971 Phase Ib/II Atezolizumab + Bendamustine + Obinutuzumab Atezolizumab + Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Atezolizumab + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) Completed USA | ITA 1
NCT02600897 Phase Ib/II Lenalidomide + Rituximab Lenalidomide + Obinutuzumab Lenalidomide + Polatuzumab vedotin-piiq + Rituximab Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Completed USA | ESP 1
NCT02603445 Phase I BCL201 + Idelalisib Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL Completed USA | FRA | DEU | AUT 0
NCT02605694 Phase II Duvelisib + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) Withdrawn USA 0
NCT02611323 Phase Ib/II Polatuzumab vedotin-piiq + Rituximab + Venetoclax Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Completed USA | ITA 1
NCT02624986 Phase Ib/II Idasanutlin + Obinutuzumab A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Terminated USA | DEU 3
NCT02626455 Phase III Vincristine Sulfate Prednisone Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib Bendamustine + Rituximab Rituximab Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 28
NCT02631044 Phase I Lisocabtagene maraleucel Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Active, not recruiting USA 0
NCT02631577 Phase I Atezolizumab + Lenalidomide + Obinutuzumab A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma Completed USA | FRA 0
NCT02650999 Phase Ib/II Pembrolizumab Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas Completed USA 0
NCT02700022 Phase I Alisertib Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas Terminated USA 0
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting USA 0
NCT02729896 Phase Ib/II Obinutuzumab + Polatuzumab vedotin-piiq + Rituximab Atezolizumab + Obinutuzumab + Polatuzumab vedotin-piiq A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Completed USA | DEU 1
NCT02743546 Phase I Ibrutinib + JNJ-64052781 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma Withdrawn 0
NCT02747043 Phase III ABP 798 Rituximab Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab (JASMINE) Completed USA | ITA | FRA | ESP | DEU | CAN 14
NCT02756247 Phase I Buparlisib + Ibrutinib A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma Active, not recruiting USA 0
NCT02776813 Phase I ACTR087 + Rituximab Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma Completed USA 0
NCT02797470 Phase Ib/II Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Recruiting USA 0
NCT02869633 Phase II Ibrutinib Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant Active, not recruiting USA 0
NCT02875223 Phase I CC-90011 A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas Active, not recruiting ITA | FRA | ESP 2
NCT02889523 Phase Ib/II Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Tazemetostat + Vincristine Sulfate Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy (Epi-RCHOP) Recruiting FRA | BEL 0
NCT02900716 Phase I DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas Completed USA 0
NCT02914938 Phase I zandelisib Rituximab + zandelisib A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Active, not recruiting USA 1
NCT02927964 Phase Ib/II Ibrutinib + Radiotherapy + SD-101 TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma Active, not recruiting USA 0
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Terminated USA 0
NCT02947347 Phase III Ibrutinib Ibrutinib + Rituximab Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma Active, not recruiting USA | ITA | FRA | ESP | CAN | BEL | AUT 13
NCT02950220 Phase I Ibrutinib + Pembrolizumab Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed USA 0
NCT02953509 Phase Ib/II Hu5F9-G4 + Rituximab Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Active, not recruiting USA 2
NCT02956382 Phase Ib/II Ibrutinib + Venetoclax Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma Recruiting USA 0
NCT02966730 Phase I Ibrutinib Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy Terminated USA 0
NCT02992522 Phase I Lenalidomide + Obinutuzumab + Venetoclax Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT03010358 Phase Ib/II Entospletinib + Obinutuzumab Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Completed USA 0
NCT03015896 Phase Ib/II Lenalidomide + Nivolumab Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Recruiting USA 0
NCT03019640 Phase II Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma Completed USA 0
NCT03039114 Phase I Bendamustine + Obinutuzumab + Parsaclisib Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) Completed USA | ITA | ESP 3
NCT03085173 Phase I EGFRt/19-28z/4-1BBL CAR T cells A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies Active, not recruiting USA 0
NCT03105336 Phase II axicabtagene ciloleucel A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5) Active, not recruiting USA | FRA 0
NCT03113422 Phase II Obinutuzumab Obinutuzumab + Venetoclax Bendamustine + Obinutuzumab + Venetoclax Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy (PrE0403) Active, not recruiting USA 0
NCT03121677 Phase I Nivolumab + Poly ICLC + Rituximab Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma Active, not recruiting USA 0
NCT03126019 Phase II Parsaclisib Idelalisib An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203) Active, not recruiting USA | ITA | ESP | DEU | CAN 8
NCT03129828 Phase Ib/II Bortezomib + Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI >= 2 (ImbruVeRCHOP) Active, not recruiting DEU 0
NCT03133221 Phase II Idelalisib 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Active, not recruiting USA 0
NCT03135262 Phase Ib/II Idasanutlin + Rituximab + Venetoclax Idasanutlin + Obinutuzumab + Venetoclax Idasanutlin + Obinutuzumab + Rituximab + Venetoclax A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) Terminated USA | DEU 3
NCT03147885 Phase Ib/II Selinexor Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT03150329 Phase I Pembrolizumab + Vorinostat Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma Active, not recruiting USA 0
NCT03153462 Expanded access axicabtagene ciloleucel + Cyclophosphamide + Fludarabine Axicabtagene Ciloleucel Expanded Access Study Approved for marketing USA 0
NCT03156114 Phase I Ezabenlimab Miptenalimab This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. Active, not recruiting USA | ESP | CAN 2
NCT03178201 Phase II Umbralisib TGR1202 in Relapsed and Refractory Follicular Lymphoma Terminated USA 0
NCT03179930 Phase II Entinostat + Pembrolizumab Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas Recruiting USA 0
NCT03189836 Phase I ACTR707 + Rituximab Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma Terminated USA 0
NCT03198026 Phase II Ibrutinib + Obinutuzumab Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas Recruiting USA 0
NCT03220347 Phase I CC-90010 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas Active, not recruiting ITA | FRA | ESP 1
NCT03245021 Phase I Nivolumab + Rituximab Nivolumab Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A (1stFLOR) Active, not recruiting 1
NCT03269669 Phase II Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Lenalidomide + Obinutuzumab Obinutuzumab + Umbralisib Prednisone Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma Suspended USA 0
NCT03277729 Phase Ib/II CD20 CAR T-cells + Cyclophosphamide + Fludarabine A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Recruiting USA 0
NCT03297424 Phase Ib/II PLX2853 A Study of PLX2853 in Advanced Malignancies. Completed USA 0
NCT03321643 Phase I Atezolizumab + Gemcitabine + Oxaliplatin + Rituximab Atezolizumab + Rituximab Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma Suspended USA 0
NCT03332017 Phase II Obinutuzumab + Zanubrutinib Obinutuzumab A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 11
NCT03341520 Phase II Obinutuzumab Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma (GAZAI) Active, not recruiting DEU 0
NCT03357627 Phase I Mivavotinib + Venetoclax A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma Completed USA | DEU | CAN 0
NCT03361852 Phase I NeoVax + Rituximab A Pilot Study of a Personalized Neoantigen Cancer Vaccine Following Front-Line Rituximab in Follicular Lymphoma Recruiting USA 0
NCT03379493 Phase I Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma Terminated USA 0
NCT03401853 Phase II Pembrolizumab + Rituximab Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma Active, not recruiting USA 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Recruiting USA | FRA | ESP | DEU 3
NCT03424122 Phase I Ibrutinib + Parsaclisib Bendamustine + Parsaclisib + Rituximab Parsaclisib + Rituximab INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) Completed USA | ITA | ESP 0
NCT03424603 Phase I STRO-001 Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Recruiting USA 0
NCT03460977 Phase I PF-06821497 PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Recruiting USA | ESP 1
NCT03465891 Phase II Atezolizumab Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma Terminated USA 0
NCT03479268 Phase I Ibrutinib + MLN4924 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT03483103 Phase II Lisocabtagene maraleucel Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) Active, not recruiting USA 0
NCT03484702 Phase II Lisocabtagene maraleucel Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD) Active, not recruiting ITA | FRA | ESP | DEU | BEL | AUT 5
NCT03498612 Phase II Pembrolizumab Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases Recruiting USA 0
NCT03533283 Phase I Obinutuzumab + RO7082859 Obinutuzumab + Polatuzumab vedotin-piiq + RO7082859 + Tocilizumab Atezolizumab + Obinutuzumab + RO7082859 + Tocilizumab An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Recruiting USA | ITA | ESP | BEL 3
NCT03547115 Phase I Voruciclib A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies Recruiting USA 0
NCT03568461 Phase II Tisagenlecleucel Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 5
NCT03571568 Phase Ib/II BI-1206 + Rituximab A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Recruiting USA | ESP 2
NCT03571828 Phase I AMG562 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma Completed USA | DEU | CAN | BEL 0
NCT03579927 Phase Ib/II Filgrastim iC9-CAR.19-IL15-Transduced CB-NK Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Withdrawn USA 0
NCT03585725 Phase I Ribavirin A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Terminated USA 0
NCT03600441 Phase II Abexinostat Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER) Active, not recruiting USA | FRA | ESP 0
NCT03610724 Phase II Tisagenlecleucel Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT 7
NCT03625037 Phase Ib/II Epcoritamab GEN3013 Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma Recruiting USA | ITA | FRA | ESP | DEU | CAN 9
NCT03636503 Phase I Avelumab + Rituximab + Utomilumab Avelumab + PF-04518600 + Rituximab PF-04518600 + Rituximab + Utomilumab RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA Active, not recruiting USA 0
NCT03671018 Phase I Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Polatuzumab vedotin-piiq + Rituximab Bendamustine + Obinutuzumab Mosunetuzumab + Polatuzumab vedotin-piiq Mosunetuzumab Obinutuzumab Tocilizumab A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma Recruiting USA | ESP | CAN | BEL 1
NCT03682796 Phase I TRPH-222 Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma Completed USA | CAN 0
NCT03685344 Phase I Durvalumab + Loncastuximab tesirine-lpyl Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma Terminated USA | ESP 0
NCT03696784 Phase I Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Recruiting USA 0
NCT03711578 Phase II Tenalisib Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) Completed USA 1
NCT03740529 Phase Ib/II Cyclophosphamide + Doxorubicin + LOXO-305 + Prednisone + Rituximab + Vincristine Sulfate LOXO-305 + Rituximab + Venetoclax LOXO-305 + Venetoclax LOXO-305 A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Recruiting USA | ITA | FRA 7
NCT03744676 Phase II Lisocabtagene maraleucel A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) Active, not recruiting USA 0
NCT03755154 Phase I VOB560 Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia Recruiting FRA | ESP 2
NCT03758989 Phase II Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma Recruiting USA 0
NCT03768505 Phase II zandelisib Study of ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies Recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 7
NCT03779113 Phase Ib/II HMPL-523 An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma Recruiting USA | ITA | ESP 2
NCT03786926 Phase Ib/II HMPL-689 Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas Recruiting USA | ITA | FRA | ESP 2
NCT03789240 Phase II Copanlisib + Rituximab Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma Recruiting USA 0
NCT03828448 Phase II Ublituximab + Umbralisib Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Naive Follicular Lymphoma Terminated USA 0
NCT03833180 Phase I VLS-101 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies Recruiting USA 0
NCT03884998 Phase I Copanlisib + Nivolumab Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma Recruiting USA 0
NCT03888105 Phase II Odronextamab Assess the Anti-Tumor Activity and Safety of REGN1979 in Patients With Relapsed or Refractory Follicular Lymphoma Recruiting USA | ITA | FRA | ESP | DEU | CAN 8
NCT03892044 Phase I Duvelisib + Nivolumab Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma Active, not recruiting USA 0
NCT03919175 Phase II Rituximab + Umbralisib Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma Recruiting USA 0
NCT03920631 Phase I Nivolumab Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) Withdrawn USA 0
NCT03939026 Phase I UCART19 ALLO-647 + Cyclophosphamide + Fludarabine Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA) Active, not recruiting USA 0
NCT03976102 Phase III Rituximab DRL_RI Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (FLINTER) Active, not recruiting USA 0
NCT03980171 Phase Ib/II Lenalidomide + Obinutuzumab + Venetoclax Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma (LEVERAGE) Recruiting USA 1
NCT04007029 Phase I Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Recruiting USA 0
NCT04014205 Phase I Orelabrutinib A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies Recruiting USA 0
NCT04038359 Phase II Duvelisib A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO) Active, not recruiting USA | ITA | DEU 5
NCT04074330 Phase Ib/II Rituximab + Subasumstat A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma Recruiting USA | ITA | FRA | ESP | DEU | CAN 3
NCT04082936 Phase I IGM-2323 A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Recruiting USA | FRA | ESP 2
NCT04136275 Phase I Anti-CD37 CAR T cells CAR-37 T Cells In Hematologic Malignancies Recruiting USA 0
NCT04156828 Phase I Carboplatin + Copanlisib + Dexamethasone + Gemcitabine + Pegfilgrastim + Rituximab Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma Recruiting USA 0
NCT04161118 Phase II huCART19 TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (TIGER-CTL019) Active, not recruiting DEU 0
NCT04205409 Phase II Nivolumab Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies Recruiting USA 0
NCT04223765 Phase I Bendamustine + CAR.k.28 cells + Fludarabine CAR.k.28 cells + Cyclophosphamide + Fludarabine Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma Recruiting USA 0
NCT04224493 Phase III Lenalidomide + Rituximab + Tazemetostat Lenalidomide + Rituximab Study in Subjects With Relapsed/Refractory Follicular Lymphoma Recruiting USA | ITA | FRA | ESP | DEU | BEL 7
NCT04231747 Phase I CC-97540 A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Recruiting USA | CAN 0
NCT04243499 Phase I ICT01 First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) Recruiting USA | FRA | ESP | DEU | BEL 1
NCT04245839 Phase II Lisocabtagene maraleucel Cyclophosphamide + Fludarabine A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL) Recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT 3
NCT04246086 Phase I Tocilizumab Obinutuzumab Lenalidomide + Obinutuzumab + RO7082859 Lenalidomide + RO7082859 Lenalidomide + Mosunetuzumab A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len) or Glofitamab + Len With or Without Obinutuzumab; and Evaluating the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With R/R Follicular Lymphoma Recruiting USA | FRA | ESP 2
NCT04263584 Phase II Copanlisib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL (COPA-R-CHOP) Recruiting DEU 0
NCT04277637 Phase I BGB-11417 + Zanubrutinib BGB-11417 Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies Recruiting USA | ESP 2
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Recruiting 2
NCT04283097 Phase I KPG-818 Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects Recruiting USA 0
NCT04390737 Phase I HH2853 A Phase I Study to Evaluate the Safety and Clinical Activity of HH2853. Recruiting USA 1
NCT04401020 Phase I SAR442257 First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL Recruiting USA | ESP 3
NCT04404088 Phase II Acalabrutinib + Lenalidomide + Rituximab Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma Recruiting USA 0
NCT04419909 Phase I huCART19 Retreatment With CTL019/CTL119 Not yet recruiting USA 0
NCT04431635 Phase I Copanlisib + Nivolumab + Rituximab Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma Recruiting USA 0
NCT04447716 Phase I Lenalidomide + Rituximab Hyaluronidase + Venetoclax Lenalidomide + Rituximab + Venetoclax An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment Recruiting USA 0
NCT04450173 Phase II Ibrutinib + Obinutuzumab + Venetoclax Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma Recruiting USA 0
NCT04464798 Phase I Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas Recruiting USA | ITA | FRA | DEU 2
NCT04491370 Phase Ib/II Polatuzumab vedotin-piiq Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma Recruiting USA 0
NCT04502706 Phase I FSI-189 FSI-189 + Rituximab Study of FSI-189 as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma Terminated USA 0
NCT04508647 Phase II Ublituximab Ublituximab + Umbralisib Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma Suspended USA 0
NCT04531046 Phase II axicabtagene ciloleucel Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation Recruiting FRA | BEL 0
NCT04540796 Phase I JNJ-75348780 A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Recruiting USA | FRA | ESP 7
NCT04569032 Phase II Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression Recruiting USA | ITA | FRA | ESP 2
NCT04578600 Phase I Azacitidine + Lenalidomide + Obinutuzumab CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Recruiting USA 0
NCT04587687 Phase II Bendamustine + Brentuximab vedotin Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma Recruiting USA 0
NCT04590820 Phase II Rituximab + Tazemetostat Oral Tazemetostat in Combination With Rituximab in R/R FL Terminated USA 0
NCT04594642 Phase I TNB-486 A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Recruiting USA 1
NCT04594798 Phase II Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL Recruiting USA 0
NCT04599634 Phase I Hu5F9-G4 + Obinutuzumab + Venetoclax Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies Recruiting USA 0
NCT04628494 Phase III Gemcitabine + Oxaliplatin + Rituximab Epcoritamab Bendamustine + Rituximab A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 16
NCT04635683 Phase I Lenalidomide + Ublituximab + Umbralisib Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Withdrawn 0
NCT04659044 Phase II Polatuzumab vedotin-piiq + Rituximab + Rituximab Hyaluronidase + Venetoclax Rituximab Hyaluronidase + Venetoclax Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Recruiting USA 0
NCT04663347 Phase Ib/II Cisplatin + Cytarabine + Dexamethasone + Epcoritamab + Rituximab Epcoritamab + Gemcitabine + Oxaliplatin Epcoritamab + Lenalidomide + Rituximab Bendamustine + Epcoritamab + Rituximab Cyclophosphamide + Doxorubicin + Epcoritamab + Prednisone + Rituximab + Vincristine Sulfate Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma Recruiting USA | ITA | FRA | ESP | BEL 8
NCT04669171 Phase Ib/II EO2463 EO2463 + Lenalidomide + Rituximab EO2463 + Rituximab A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY) Recruiting USA | ITA | ESP 0
NCT04680052 Phase III Lenalidomide + Rituximab Lenalidomide + Rituximab + Tafasitamab-cxix A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 17
NCT04699461 Phase II Idelalisib Loncastuximab tesirine-lpyl Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS 6) Active, not recruiting USA | ITA | FRA | ESP | BEL 5
NCT04712097 Phase III Lenalidomide + Mosunetuzumab + Tocilizumab Lenalidomide + Rituximab + Tocilizumab A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy Recruiting USA | ITA | FRA | ESP | DEU 11
NCT04722601 Phase Ib/II Azacitidine + Venetoclax Azacitidine + Obinutuzumab + Venetoclax Obinutuzumab A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma Recruiting USA 0
NCT04728893 Phase II ARQ 531 Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (MK-1026-003) Recruiting USA | ITA | FRA | ESP | CAN 9
NCT04745832 Phase III Rituximab + zandelisib Bendamustine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) Recruiting USA | ITA | FRA | ESP | CAN | BEL 13
NCT04750941 Phase II Copanlisib Study of Copanlisib and Ketogenic Diet Recruiting USA 0
NCT04762160 Phase II Rituximab + Tazemetostat A Trial to Examine Combination of Tazemetostat and Rituximab for Patients With Recurrent/Refractory Follicular Lymphoma Recruiting USA 0
NCT04775745 Phase I LP-168 Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. Recruiting USA 0
NCT04792502 Phase II Lenalidomide + Mosunetuzumab Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma Recruiting USA 0
NCT04799275 Phase II Azacitidine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Suspended USA 0
NCT04809467 Phase Ib/II Parsaclisib + Tafasitamab-cxix A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 0
NCT04824092 Phase III Cyclophosphamide + Doxorubicin + Lenalidomide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND) Recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT 22
NCT04830137 Phase I NX-2127 A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting USA 0
NCT04836195 Phase I PCLX-001 Phase I Trial of PCLX-001 in B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies Recruiting CAN 0
NCT04836832 Phase I Acalabrutinib + Duvelisib Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Withdrawn 0
NCT04842877 Phase II DS-3201b Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma Recruiting FRA | BEL 0
NCT04844866 Phase II Bendamustine + Polatuzumab vedotin-piiq + Rituximab Gemcitabine + Oxaliplatin + Rituximab Zamtocabtagene autoleucel Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients Recruiting ITA | FRA | ESP | DEU | BEL | AUT 6
NCT04853329 Phase Ib/II CPO107 Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma Recruiting USA 0
NCT04861779 Phase I HSK29116 A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting 2
NCT04882163 Phase Ib/II Cisplatin + Dexamethasone + Gemcitabine + Iberdomide + Rituximab Lenalidomide + Tafasitamab-cxix Iberdomide + Polatuzumab vedotin-piiq + Rituximab Iberdomide + Tafasitamab-cxix Bendamustine + Polatuzumab vedotin-piiq + Rituximab Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma Withdrawn USA | FRA | ESP | BEL | AUT 3
NCT04883437 Phase II Acalabrutinib + Obinutuzumab Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Recruiting USA 0
NCT04889716 Phase II Obinutuzumab + RO7082859 Mosunetuzumab CAR-T Followed by Bispecific Antibodies Recruiting USA 0
NCT04903197 Phase I Lenalidomide + VAY736 VAY736 Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma Recruiting USA | ITA | ESP | DEU 4
NCT04962126 Phase II Atezolizumab + Obinutuzumab Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (FLUORO) Recruiting 1
NCT04974216 Phase II Lenalidomide + Rituximab + Tafasitamab-cxix Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older Recruiting FRA | BEL 0
NCT04975555 Phase II Siltuximab Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Recruiting USA 0
NCT04980222 Phase II Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + RO7082859 + Vincristine Sulfate A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma Recruiting USA | FRA | ESP 3
NCT04998669 Phase II Loncastuximab tesirine-lpyl + Rituximab Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma Recruiting USA 0
NCT05003141 Phase I PSB202 PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies Recruiting USA 2
NCT05005442 Phase II MK-7684A A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004) Recruiting USA | ITA | FRA | ESP | DEU | CAN 10
NCT05006716 Phase I BGB-16673 A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies Recruiting USA 1
NCT05008055 Phase II Capivasertib Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL) Recruiting USA | FRA | ESP | CAN 3
NCT05010005 Phase I Duvelisib + Ruxolitinib A Study of Ruxolitinib and Duvelisib in People With Lymphoma Recruiting USA 0
NCT05025800 Phase Ib/II Evorpacept + Lenalidomide + Rituximab ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT05131022 Phase I NX-5948 Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting 1
NCT05152459 Phase Ib/II Tazemetostat + Ublituximab + Umbralisib Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma Not yet recruiting USA 0
NCT05169515 Phase I Iberdomide + RO7082859 CC-99282 + RO7082859 CC-99282 + Mosunetuzumab Iberdomide + Mosunetuzumab A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma Recruiting 2
NCT05169658 Phase II Mosunetuzumab + Obinutuzumab + Polatuzumab vedotin-piiq Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT05171647 Phase III Mosunetuzumab + Polatuzumab vedotin-piiq Mosunetuzumab + Polatuzumab vedotin-piiq + Tocilizumab Gemcitabine + Oxaliplatin + Rituximab A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO) Recruiting 8
NCT05205161 Phase Ib/II AZD0466 A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma Recruiting USA | ITA | FRA | ESP | CAN 3
NCT05207670 Phase II Mosunetuzumab + Tocilizumab A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) Recruiting USA 0
NCT05211336 Phase I Lenalidomide + Nivolumab Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System Suspended USA 0
NCT05256641 Phase Ib/II Acalabrutinib Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma Not yet recruiting USA 0
NCT05260957 Phase II Mosunetuzumab + Polatuzumab vedotin-piiq CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). Not yet recruiting USA 0
NCT05283720 Phase II Epcoritamab + Lenalidomide Epcoritamab + Ibrutinib + Lenalidomide Cyclophosphamide + Doxorubicin + Epcoritamab + Polatuzumab vedotin-piiq + Prednisone + Rituximab A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma Recruiting USA | FRA | ESP | DEU | CAN 9
NCT05296525 Phase Ib/II GDA-201 Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL Recruiting USA 0
NCT05315713 Phase Ib/II Mosunetuzumab + Tiragolumab + Tocilizumab Atezolizumab + Mosunetuzumab + Tiragolumab + Tocilizumab An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma Recruiting USA | CAN | BEL 2
NCT05359211 Phase I NKTR-255 Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Recruiting USA 0
NCT05371093 Phase III axicabtagene ciloleucel Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Fludarabine Bendamustine + Rituximab Lenalidomide + Rituximab Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ZUMA-22) Recruiting USA 0
NCT05387616 Phase II Copanlisib + Obinutuzumab A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden (Alternative-C) Recruiting DEU 0
NCT05389293 Phase II Mosunetuzumab A Study of Mosunetuzumab in People With Follicular Lymphoma Recruiting USA 0
NCT05409066 Phase III Lenalidomide + Rituximab Epcoritamab + Lenalidomide + Rituximab Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 22
NCT05410418 Phase II Mosunetuzumab + Polatuzumab vedotin-piiq Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma Not yet recruiting USA 0
NCT05412290 Phase I Mosunetuzumab Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma Not yet recruiting USA 0
NCT05421663 Phase I C-CAR039 A Study of C-CAR039 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT05451810 Phase II Epcoritamab A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Recruiting USA 0
NCT05453396 Phase II Loncastuximab tesirine-lpyl Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Not yet recruiting USA 0
NCT05455697 Phase Ib/II Cyclophosphamide + Doxorubicin + Prednisone + Retifanlimab + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the Treatment of Diffuse Large B-cell Lymphoma Not yet recruiting USA 0
NCT05458297 Phase II VLS-101 ARQ 531 + VLS-101 A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination With Nemtabrutinib (MK-1026) in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) Recruiting USA | ESP 2
NCT05459571 Phase II axicabtagene ciloleucel + Cyclophosphamide + Dexamethasone + Fludarabine Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (ZUMA-24) Recruiting USA 0
NCT05464329 Phase I Mosunetuzumab Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma Not yet recruiting USA 0
NCT05507541 Phase II Pembrolizumab + TTI-622 Pembrolizumab + TTI-621 TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Not yet recruiting USA 0
NCT05512390 Phase I ABBV-319 A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) Not yet recruiting USA 0